Which Small-Cap Value ETF Is Better: State Street's SLYV or iShares' ISCV?

ISCV offers the lower expense ratio at 0.06% versus SLYV’s 0.15%, while matching its dividend yield at about 2.0% and posting a smaller 5-year drawdown of -25.34% versus -28.67%. It also provides broader diversification with over 1,000 holdings compared with SLYV’s roughly 460, though SLYV has stronger 1-year performance at 45.1% versus 36.1%. The article is primarily a comparative ETF analysis and is unlikely to move prices materially.

Analysis

The real signal here is not a winner-take-all verdict between two nearly identical factor vehicles; it is that small-cap value is still being bid as a portfolio-level diversifier, not a pure alpha bet. The tighter fees and broader basket in ISCV make it the cleaner implementation for strategic allocators, while SLYV’s higher AUM and profitability screen likely make it the preferred tactical hold for investors who want a slightly higher-quality small-value basket with more trading depth. That split matters because in a market where rates have stopped falling in a straight line, the cheapest way to own cyclical beta with some income support is likely to keep attracting flows even if leadership rotates.

Second-order effects are more interesting than the headline comparison. ISCV’s deeper-value tilt and lack of a profitability filter increase exposure to balance-sheet repair stories, refinancing sensitivity, and commodity/industrial operating leverage; that helps names tied to cyclical recovery but also raises the probability of value traps if credit conditions tighten again. SLYV’s relative quality screen should dampen downside in a macro wobble, which means the spread between the two funds can become a live rate-sensitive barometer: ISCV should outperform in easing/liquidity-friendly windows, while SLYV should hold up better if financing conditions deteriorate.

The market is likely underpricing how much of this segment’s recent strength is coming from positioning rather than fundamentals. After a strong 12-month run, a lot of incremental capital may be chasing small-cap value as a late-cycle/early-easing trade, making the segment vulnerable to a sharp but brief mean reversion if growth or inflation data re-accelerate. That said, the lower fee on ISCV compounds materially over multi-year horizons, so the right answer depends on whether the buyer is optimizing for next-quarter factor beta or a three-to-five-year strategic allocation.

The clean contrarian read is that the ‘better ETF’ may not be the one with the slightly better past drawdown or lower fee, but the one that best matches the regime. If rates stay elevated and dispersion increases, the quality tilt in SLYV may command a higher multiple of flows despite the higher fee; if the Fed pivots decisively and funding stress recedes, ISCV’s more aggressive value exposure should create more upside torque. In other words, this is less about product design and more about which macro regime investors are implicitly betting on.

Key Decisions for Investors

• Long ISCV / short SLYV as a 3-6 month pairs trade if your house view is easing liquidity and stronger small-cap reflexivity; target modest spread outperformance, but cap risk if credit spreads widen or growth data rolls over.
• Use SLYV as the preferred parking vehicle for tactical small-cap value exposure over the next 1-2 quarters if macro uncertainty remains elevated; its profitability screen should be the better downside buffer in a risk-off tape.
• Accumulate ISCV on pullbacks for a 2-3 year strategic allocation if the goal is lower-fee factor exposure; the fee gap compounds enough to matter, especially in a low-single-digit expected return sleeve.
• Avoid adding both funds simultaneously unless intentional style overlap is desired; they are close substitutes, so holding both dilutes the ability to express a clear regime view and adds redundant small-cap value beta.
• If rates re-accelerate higher, hedge ISCV first and keep SLYV as the residual hold: the deeper-value, lower-quality tilt should be more vulnerable to funding-sensitive drawdowns.